PT2164961E - Manipulação baseada em sequências e otimização de anticorpos de cadeia única - Google Patents
Manipulação baseada em sequências e otimização de anticorpos de cadeia única Download PDFInfo
- Publication number
- PT2164961E PT2164961E PT87572772T PT08757277T PT2164961E PT 2164961 E PT2164961 E PT 2164961E PT 87572772 T PT87572772 T PT 87572772T PT 08757277 T PT08757277 T PT 08757277T PT 2164961 E PT2164961 E PT 2164961E
- Authority
- PT
- Portugal
- Prior art keywords
- optimization
- single chain
- chain antibodies
- sequence based
- based engineering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Microbiology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Evolutionary Biology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Transplantation (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93711207P | 2007-06-25 | 2007-06-25 | |
US6905708P | 2008-03-12 | 2008-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2164961E true PT2164961E (pt) | 2015-04-08 |
Family
ID=39855147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT87572772T PT2164961E (pt) | 2007-06-25 | 2008-06-25 | Manipulação baseada em sequências e otimização de anticorpos de cadeia única |
Country Status (20)
Country | Link |
---|---|
US (1) | US9908945B2 (pt) |
EP (1) | EP2164961B1 (pt) |
JP (2) | JP5506670B2 (pt) |
KR (1) | KR101530723B1 (pt) |
CN (1) | CN101688200B (pt) |
AU (1) | AU2008267733B2 (pt) |
BR (1) | BRPI0813287A2 (pt) |
CA (1) | CA2689064C (pt) |
DK (1) | DK2164961T3 (pt) |
ES (1) | ES2532725T3 (pt) |
HK (1) | HK1137035A1 (pt) |
IL (1) | IL202352A (pt) |
MX (1) | MX2009013327A (pt) |
NZ (1) | NZ581470A (pt) |
PL (1) | PL2164961T3 (pt) |
PT (1) | PT2164961E (pt) |
RU (1) | RU2010102064A (pt) |
SI (1) | SI2164961T1 (pt) |
WO (1) | WO2009000098A2 (pt) |
ZA (1) | ZA200908314B (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101457223B1 (ko) * | 2005-06-07 | 2014-11-04 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | TNFα를 억제하는 안정적이고 가용성인 항체 |
DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
EP2118138A1 (en) | 2007-03-12 | 2009-11-18 | Esbatech AG | Sequence based engineering and optimization of single chain antibodies |
RU2010102064A (ru) | 2007-06-25 | 2011-07-27 | Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch) | Способ конструирования, основанный на определении последовательностей, способ оптимизации одноцепочечных антител |
MX2009013328A (es) | 2007-06-25 | 2010-06-02 | Esbatech An Alcon Biomedical R | Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas. |
HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
ES2884117T3 (es) | 2008-06-25 | 2021-12-10 | Novartis Ag | Optimización de la solubilidad de inmunoaglutinantes |
PT2307457T (pt) | 2008-06-25 | 2018-10-16 | Esbatech Alcon Biomed Res Unit | Anticorpos estáveis e solúveis que inibem o tnf |
EP3216803B1 (en) | 2008-06-25 | 2020-03-11 | Novartis Ag | Stable and soluble antibodies inhibiting vegf |
KR102007492B1 (ko) | 2008-06-25 | 2019-08-05 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
EP2304033B1 (en) | 2008-06-30 | 2016-09-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Functionalized polypeptides |
KR20110031373A (ko) | 2008-07-10 | 2011-03-25 | 에스바테크, 언 알콘 바이오메디칼 리서치 유닛 엘엘씨 | 마크로분자 전달을 증강하는 방법 및 조성물 |
US8399624B1 (en) | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
MY160124A (en) * | 2009-12-22 | 2017-02-28 | Hoffmann La Roche | Sequence dependent aggregation |
EP3498731A1 (en) | 2009-12-23 | 2019-06-19 | ESBATech, an Alcon Biomedical Research Unit LLC | Method for decreasing immunogenicity |
EP2593594B1 (en) * | 2010-07-16 | 2017-09-27 | Adimab, LLC | Antibody libraries |
JP5704386B2 (ja) * | 2010-10-12 | 2015-04-22 | 日本電気株式会社 | タンパク質分子のアミノ酸置換部位選択装置、置換アミノ酸選択装置、アミノ酸置換部位選択方法、置換アミノ酸選択方法、プログラムおよび記録媒体 |
AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
EP2476754A1 (en) * | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
KR101287625B1 (ko) * | 2011-10-10 | 2013-07-23 | 대유라디에터공업 주식회사 | 열교환기용 튜브 제조방법 |
JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
TWI636062B (zh) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
TWI779010B (zh) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
EP3253778A1 (en) | 2015-02-05 | 2017-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
GB201502590D0 (en) * | 2015-02-16 | 2015-04-01 | Lonza Ag | Method and apparatus for designing proteins |
CN107002074B (zh) * | 2015-06-10 | 2021-08-10 | 公立大学法人富山县立大学 | 活性型突变酶的制造方法及活性型突变酶、以及可溶性化突变蛋白的制造方法 |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CA3093729A1 (en) | 2018-03-15 | 2019-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
JP2024508736A (ja) | 2021-02-12 | 2024-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 補体c3抗原結合タンパク質 |
AU2022233285A1 (en) | 2021-03-09 | 2023-10-19 | Cdr-Life Ag | Mage-a4 peptide-mhc antigen binding proteins |
US20220340894A1 (en) | 2021-03-09 | 2022-10-27 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
KR20240116828A (ko) | 2021-12-14 | 2024-07-30 | 씨디알-라이프 아게 | 이중 mhc-표적화 t 세포 관여자 |
WO2023220038A1 (en) * | 2022-05-10 | 2023-11-16 | Amgen Inc. | Machine learning techniques for predicting thermostability |
US20240091262A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
WO2024122449A1 (ja) * | 2022-12-06 | 2024-06-13 | 株式会社レボルカ | 機械学習による抗体設計法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
NZ512006A (en) | 1996-02-09 | 2005-05-27 | Abbott Biotech Ltd | Medical treatment with human TNF-alpha antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
DE69939939D1 (de) | 1998-08-11 | 2009-01-02 | Idec Pharma Corp | Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
ES2224737T3 (es) | 1998-12-14 | 2005-03-01 | Osteotech, Inc., | Injerto de hueso hecho de particulas oseas. |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
DK1242457T3 (da) | 1999-12-28 | 2004-12-20 | Esbatech Ag | Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf |
EP2287191B1 (en) | 2000-05-10 | 2016-10-12 | Mayo Foundation For Medical Education And Research | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
PT1390535E (pt) | 2001-04-26 | 2010-10-04 | Amgen Mountain View Inc | Bibliotecas combinatórias de domínios monoméricos |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
EP1406931A2 (en) | 2001-07-19 | 2004-04-14 | Universität Zürich | Modification of human variable domains |
DK1506236T3 (da) | 2002-05-22 | 2013-03-04 | Esbatech A Novartis Co Llc | Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf |
US20050033029A1 (en) | 2003-06-30 | 2005-02-10 | Jin Lu | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
KR20120108061A (ko) | 2003-11-28 | 2012-10-04 | 다이엑스 코포레이션 | 아포지단백질 e의 c말단 단편에 결합하는 항체 |
CA2564251C (en) | 2004-05-21 | 2018-04-10 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
KR101457223B1 (ko) | 2005-06-07 | 2014-11-04 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | TNFα를 억제하는 안정적이고 가용성인 항체 |
US7838638B2 (en) | 2005-12-13 | 2010-11-23 | Eli Lilly And Company | Anti-IL-17 antibodies |
RU2438708C2 (ru) | 2006-07-10 | 2012-01-10 | Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк | ScFv-АНТИТЕЛА, КОТОРЫЕ ПРОХОДЯТ ЧЕРЕЗ ЭПИТЕЛИАЛЬНЫЙ И/ИЛИ ЭНДОТЕЛИАЛЬНЫЙ СЛОИ |
EP2118138A1 (en) * | 2007-03-12 | 2009-11-18 | Esbatech AG | Sequence based engineering and optimization of single chain antibodies |
RU2010102064A (ru) | 2007-06-25 | 2011-07-27 | Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch) | Способ конструирования, основанный на определении последовательностей, способ оптимизации одноцепочечных антител |
MX2009013328A (es) | 2007-06-25 | 2010-06-02 | Esbatech An Alcon Biomedical R | Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas. |
-
2008
- 2008-06-25 RU RU2010102064/10A patent/RU2010102064A/ru unknown
- 2008-06-25 EP EP08757277.2A patent/EP2164961B1/en active Active
- 2008-06-25 CA CA2689064A patent/CA2689064C/en not_active Expired - Fee Related
- 2008-06-25 BR BRPI0813287-9A2A patent/BRPI0813287A2/pt not_active Application Discontinuation
- 2008-06-25 NZ NZ581470A patent/NZ581470A/xx not_active IP Right Cessation
- 2008-06-25 WO PCT/CH2008/000284 patent/WO2009000098A2/en active Application Filing
- 2008-06-25 SI SI200831414T patent/SI2164961T1/sl unknown
- 2008-06-25 MX MX2009013327A patent/MX2009013327A/es active IP Right Grant
- 2008-06-25 CN CN200880021937XA patent/CN101688200B/zh active Active
- 2008-06-25 AU AU2008267733A patent/AU2008267733B2/en not_active Ceased
- 2008-06-25 DK DK08757277.2T patent/DK2164961T3/en active
- 2008-06-25 KR KR1020097027050A patent/KR101530723B1/ko active IP Right Grant
- 2008-06-25 JP JP2010513600A patent/JP5506670B2/ja active Active
- 2008-06-25 US US12/145,749 patent/US9908945B2/en active Active
- 2008-06-25 ES ES08757277.2T patent/ES2532725T3/es active Active
- 2008-06-25 PL PL08757277T patent/PL2164961T3/pl unknown
- 2008-06-25 PT PT87572772T patent/PT2164961E/pt unknown
-
2009
- 2009-11-24 ZA ZA2009/08314A patent/ZA200908314B/en unknown
- 2009-11-26 IL IL202352A patent/IL202352A/en active IP Right Grant
-
2010
- 2010-04-09 HK HK10103507.8A patent/HK1137035A1/xx not_active IP Right Cessation
-
2013
- 2013-10-17 JP JP2013216065A patent/JP2014051508A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1137035A1 (en) | 2010-07-16 |
JP2010532324A (ja) | 2010-10-07 |
EP2164961B1 (en) | 2015-01-07 |
AU2008267733A1 (en) | 2008-12-31 |
IL202352A0 (en) | 2011-08-01 |
US9908945B2 (en) | 2018-03-06 |
DK2164961T3 (en) | 2015-03-02 |
US20090028848A1 (en) | 2009-01-29 |
IL202352A (en) | 2015-06-30 |
PL2164961T3 (pl) | 2015-08-31 |
RU2010102064A (ru) | 2011-07-27 |
CA2689064C (en) | 2018-04-24 |
ZA200908314B (en) | 2011-02-23 |
NZ581470A (en) | 2013-04-26 |
AU2008267733B2 (en) | 2013-11-14 |
EP2164961A2 (en) | 2010-03-24 |
WO2009000098A3 (en) | 2009-04-23 |
ES2532725T3 (es) | 2015-03-31 |
KR20100028053A (ko) | 2010-03-11 |
CA2689064A1 (en) | 2008-12-31 |
BRPI0813287A2 (pt) | 2014-12-30 |
JP5506670B2 (ja) | 2014-05-28 |
CN101688200B (zh) | 2012-08-08 |
KR101530723B1 (ko) | 2015-06-22 |
WO2009000098A2 (en) | 2008-12-31 |
SI2164961T1 (sl) | 2015-05-29 |
JP2014051508A (ja) | 2014-03-20 |
MX2009013327A (es) | 2010-06-02 |
CN101688200A (zh) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1137035A1 (en) | Sequence based engineering and optimization of single chain antibodies | |
HK1138602A1 (en) | Sequence based engineering and optimization of single chain antibodies | |
IL248723B (en) | Specific antibodies against the bcr complex and methods of using them | |
HRP20160684T1 (hr) | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću | |
EP1999470A4 (en) | IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF | |
ZA201106118B (en) | Anti-vegf antibody compositions and methods | |
ZA200900395B (en) | Antibodies directed to +-Vß6 and uses thereof | |
HK1194395A1 (zh) | 抗體及其製備和使用方法 | |
HK1138329A1 (zh) | 包含抗體代理輕鏈序列的構建和文庫 | |
IL192419A0 (en) | Anti-ephb4 antibodies and methods using same | |
HK1142341A1 (en) | Anti-hepcidin antibodies and uses thereof | |
IL197937A0 (en) | Antibodies to lymphotoxin-alpha | |
IL231891A (en) | Anti-ephrinb2 antibodies and methods for their use | |
ZA200806053B (en) | Anti-EphB4 antibodies and methods using same | |
ZA200902346B (en) | Antibodies to lymphotoxin-alpha | |
PL384339A1 (pl) | Wyprażacz łańcuchowy | |
HUP0600762A2 (en) | Delaying chain |